Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)’s share price was up 5.3% on Thursday . The stock traded as high as $151.79 and last traded at $149.49, with a volume of 3,289,147 shares traded. The stock had previously closed at $141.91.

JAZZ has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, July 20th. SunTrust Banks Inc. raised shares of Jazz Pharmaceuticals PLC from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $164.00 to $200.00 in a research note on Monday, April 25th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $188.00 price objective (up previously from $186.00) on shares of Jazz Pharmaceuticals PLC in a research note on Monday, June 6th. Mizuho reaffirmed a “hold” rating on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, April 13th. Finally, BMO Capital Markets initiated coverage on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, June 28th. They set an “outperform” rating and a $190.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company’s stock. Jazz Pharmaceuticals PLC has a consensus rating of “Buy” and a consensus target price of $185.36.

The firm has a market capitalization of $9.12 billion and a PE ratio of 28.48. The firm has a 50 day moving average price of $142.68 and a 200 day moving average price of $137.30.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported $2.26 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.31 by $0.05. The firm had revenue of $336 million for the quarter, compared to analysts’ expectations of $338.86 million. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.99 EPS. Equities research analysts predict that Jazz Pharmaceuticals PLC will post $11.14 earnings per share for the current year.

In other news, CMO Karen L. Smith bought 557 shares of the firm’s stock in a transaction on Monday, June 13th. The shares were bought at an average price of $149.61 per share, for a total transaction of $83,332.77. Following the purchase, the chief marketing officer now owns 12,994 shares in the company, valued at $1,944,032.34. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Karen L. Smith bought 580 shares of the firm’s stock in a transaction on Wednesday, July 13th. The shares were purchased at an average price of $143.63 per share, for a total transaction of $83,305.40. Following the purchase, the chief marketing officer now owns 13,574 shares in the company, valued at approximately $1,949,633.62. The disclosure for this purchase can be found here.

Other large investors have recently added to or reduced their stakes in the company. BlackRock Advisors LLC boosted its stake in Jazz Pharmaceuticals PLC by 119.4% in the fourth quarter. BlackRock Advisors LLC now owns 311,095 shares of the specialty pharmaceutical company’s stock worth $43,728,000 after buying an additional 169,312 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in Jazz Pharmaceuticals PLC by 8.2% in the fourth quarter. Westfield Capital Management Co. LP now owns 2,487,288 shares of the specialty pharmaceutical company’s stock worth $349,613,000 after buying an additional 188,562 shares during the last quarter. Nicholas Co. Inc. WI boosted its stake in Jazz Pharmaceuticals PLC by 55.7% in the fourth quarter. Nicholas Co. Inc. WI now owns 675,230 shares of the specialty pharmaceutical company’s stock worth $94,910,000 after buying an additional 241,605 shares during the last quarter. KBC Group NV boosted its stake in Jazz Pharmaceuticals PLC by 9.2% in the fourth quarter. KBC Group NV now owns 99,296 shares of the specialty pharmaceutical company’s stock worth $13,957,000 after buying an additional 8,353 shares during the last quarter. Finally, Affinity Investment Advisors LLC boosted its stake in Jazz Pharmaceuticals PLC by 24.1% in the fourth quarter. Affinity Investment Advisors LLC now owns 26,050 shares of the specialty pharmaceutical company’s stock worth $3,662,000 after buying an additional 5,060 shares during the last quarter.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.